Page 67 - 2020_01-Haematologica-web

Donor lymphocyte infusion in haplo-HCT
tion with peripheral blood stem cell grafts and PTCy. Bone Marrow Transplant. 2017;52(12):1623-1628.
31. Yan CH, Liu DH, Liu KY, et al. Risk stratifi- cation-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood. 2012;119(14):3256-3262.
32. Yan CH, Liu QF, Wu DP, et al. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-ver- sus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia. Biol Blood Marrow Transplant. 22017;23(8):1311-1319.
33. Yan CH, Wang JZ, Liu DH, et al. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors. Eur J Haematol. 2013;91(4):304-314.
34. Ma YR, Xu LP, Zhang XH, et al. Comparable post-relapse outcomes between haploidenti- cal and matched related donor allogeneic stem cell transplantation. Bone Marrow Transplant. 2017;52(3):409-414.
35. Mo XD, Zhang XH, Xu LP, et al. Comparison of outcomes after donor lym- phocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syn- drome after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2017;96 (5):829-838.
36. Mo XD, Zhang XH, Xu LP, et al. Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host dis- ease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clini- cal outcomes. Eur J Haematol. 2016;96(3): 297-308.
37. Mo XD, Qin YZ, Zhang XH, et al. Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syn- drome after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2016;95(8):1233-1240.
38. Huang XJ, Liu DH, Liu KY, et al. Donor lym- phocyte infusion for the treatment of leukemia relapse after HLA- mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica. 2007;92(3):414-417.
39. Yan CH, Xu LP, Liu DH, et al. Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT. Clin Transplant. 2015;29(7):594-605.
40. Buckley SA, Wood BL, Othus M, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis, Haematologica. 2017;102(5):865-873.
41. Shen Z, Gu X, Mao W, et al. Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis. BMC Cancer. 2018;18(1):755.
42. Canaani J, Labopin M, Huang XJ, et al. Minimal residual disease status predicts out-
come of acute myeloid leukaemia patients undergoing T-cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2018;183(3):411-420.
43. Lee HC, Saliba RM, Rondon G, et al. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2015;21(11):1948-1954.
44. Koreth J, Kim HT, Nikiforow S, et al. Donor chimerism early after reduced-intensity con- ditioning hematopoietic stem cell transplan- tation predicts relapse and survival. Biol Blood Marrow Transplant. 22014;20(10): 1516-1521.
45. Solomon SR, Sizemore CA, Zhang X, et al. Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial. Bone Marrow Transplant. 2014;49(5):616-621.
46. Di Grazia C, Pozzi S, Geroldi S, et al. Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016;22(7):1242-1246.
47. Tan Y, Du K, Luo Y, et al. Superiority of pre- emptive donor lymphocyte infusion based on minimal residual disease in acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Transfusion. 2014;54(6):1493-1500.
48. Shah MV, Jorgensen JL, Saliba RM, et al. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2018;24(7): 1514-1520.
49. Keil F, Haas OA, Fritsch G, et al. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts apla- sia. Blood. 1997;89(9):3113-3117.
50. Schmid C, Schleuning M, Ledderose G, et al. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogene- ic stem-cell transplantation, and prophylac- tic donor lymphocyte transfusion in high- risk acute myeloid leukemia and myelodys- plastic syndrome. J Clin Oncol. 2005;23(24): 5675-5687.
51. Tsirigotis P, Liga M, Gkirkas K, et al. Low- dose alemtuzumab for GvHD prevention followed by prophylactic donor lymphocyte infusions in high-risk leukemia. Bone Marrow Transplant. 2017;52(3):445-451.
52. Maschan M, Blagov S, Shelikhova L, et al. Low-dose donor memory T-cell infusion after TCR alpha/beta depleted unrelated and haploidentical transplantation: results of a pilot trial. Bone Marrow Transplant. 2018;53(3):264-273.
53. Schmid C, Labopin M, Schaap N, et al. Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT. Br J Haematol. 2018;184(5):782-787.
54. Gao XN, Lin J, Wang SH, et al. Donor lym- phocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies.
Ann Hematol. 2018;98(1):185-193.
55. Jaiswal SR, Zaman S, Nedunchezhian M, et al. CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: A pilot study. Cytotherapy.
2017;19(4):531-542.
56. Jaiswal SR, Zaman S, Chakrabarti A, et al.
Improved Outcome of Refractory/Relapsed Acute Myeloid Leukemia after Post- Transplantation Cyclophosphamide-Based Haploidentical Transplantation with Myeloablative Conditioning and Early Prophylactic Granulocyte Colony- Stimulating Factor-Mobilized Donor Lymphocyte Infusions. Biol Blood Marrow Transplant. 2016;22(10):1867-1873.
57. Yan CH, Wang Y, Wang JZ, et al. Minimal residual disease- and graft-vs.-host disease- guided multiple consolidation chemothera- py and donor lymphocyte infusion prevent second acute leukemia relapse after allo- transplant. J Hematol Oncol. 2016;9(1):87.
58. Nagler A, Ackerstein A, Or R, et al. Adoptive immunotherapy with haploidentical allo- geneic peripheral blood lymphocytes fol- lowing autologous bone marrow transplan- tation. Exp Hematol. 2000;28(11):1225- 1231.
59. Call SK, Kasow KA, Barfield R, et al. Total and active rabbit antithymocyte globulin (rATG;Thymoglobulin) pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant. 2009;15(2):274- 278.
60. Gilman AL, Leung W, Cowan MJ, et al. Donor lymphocyte infusion and methotrex- ate for immune recovery after T-cell deplet- ed haploidentical transplantation. Am J Hematol. 2018;93(2):169-178.
61. Martelli MF, Di Ianni M, Ruggeri L, et al. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood. 2014;124(4):638-644.
62. Dodero A, Carniti C, Raganato A, et al. Haploidentical stem cell transplantation after a reduced-intensity conditioning regi- men for the treatment of advanced hemato- logic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood. 2009;113(19):4771-4779.
63. Perruccio K, Tosti A, Burchielli E, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood. 2005;106(13):4397-4406.
64. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9(9):1144- 1150.
65. Lewalle P, Triffet A, Delforge A, et al. Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study. Bone Marrow Transplant. 2003;31(1):39-44.
66. Wang Y, Liu DH, Xu LP, et al. Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/hap- loidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analy- sis. Bone Marrow Transplant. 2012;47(8): 1099-1104.
haematologica | 2020; 105(1)
57